<DOC>
	<DOCNO>NCT00838097</DOCNO>
	<brief_summary>This European study observes paediatric patient Chronic Kidney Disease use Darbepoetin Alfa assess drug 's long term safety profile pattern use within population .</brief_summary>
	<brief_title>European Union Registry Paediatric Chronic Kidney Disease Patients Looking Safety Usage Patterns Darbepoetin Alfa</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Anaemia attribute Chronic Kidney Disease ( CKD ) Sixteen year age Documented CKD demonstrate estimate glomerular filtration rate ( eGFR ) &lt; 60 mL/min/1.73m² ( Schwartz equation ) ≥3 month dialysis , : Receiving dialysis Treatment darbepoetin alfa Documented inform consent parent authorise individual , require , assent patient appropriate Active malignancy current chemotherapy radiation therapy Investigator unlikely able obtain adequate followup information , participant available followup assessment Currently enrol yet complete least 30 day since end investigational device drug study ; subject receive investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>CKD</keyword>
	<keyword>Paediatric</keyword>
	<keyword>Darbepoetin Alfa</keyword>
</DOC>